Pulnovo Medical Limited, a China-based globally device company in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), announced on Tuesday that it has enrolled the first two patients for its global multicentre clinical study exploring the percutaneous pulmonary artery denervation (PADN) technology intended for the treatment of pulmonary hypertension related to left heart disease.

This event took place at Centro Hospitalar Universitario de Lisboa Central - Hospital de Santa Marta in Portugal, marking the beginning of Pulnovo Medical's innovative product deployment on a global scale.

Under the guidance of Professor Hang Zhang from Nanjing Medical University Affiliated Nanjing Hospital, Professor Ruben Ramos and his team successfully performed the PADN procedure on two patients. Pulnovo said that the procedure was smooth, the devices easy to operate, and the results were excellent. It added that the Portuguese medical team was impressed by the PADN technology's safety and efficacy, as demonstrated by many years of data. Clinical parameters showed promising results when using PADN technology. The products' comprehensive design and high-precision algorithm control significantly ensured stable energy output and effective surgical results.

Professor Ramos stated: "PADN technology shows great potential in treating pulmonary hypertension associated with left heart disease. We are delighted to be the first in Europe to participate in this global clinical study. Our team is confident in this project and looks forward to bringing more treatment options to European pulmonary hypertension patients through this study. PADN is not only a new treatment method but also brings new hope to patients suffering from pulmonary hypertension."